YM Biosciences YM Biosciences

YM Biosciences

9B07N010

    • $3.99
    • $3.99

Publisher Description

The chairman and chief executive officer (CEO) of Ontario-based YM Biosciences (YM), was preparing for the upcoming board meeting. During this meeting several items of strategic importance would be discussed. Two potential acquisitions were being contemplated. In order to prepare for this meeting, the chairman would have to assess the strategic impact of each of the potential acquisitions and the way in which the acquisitions should be conducted.

GENRE
Business & Personal Finance
RELEASED
2008
March 6
LANGUAGE
EN
English
LENGTH
17
Pages
PUBLISHER
Richard Ivey School of Business Foundation
SELLER
Ivey Business School Foundation
SIZE
2.3
MB
An Analysis of the Initial Adoption of FAS 141 and 142 in the Pharmaceutical Industry. An Analysis of the Initial Adoption of FAS 141 and 142 in the Pharmaceutical Industry.
2006
Pharmaxis: A Star Performer at Commercialization Crossroads Pharmaxis: A Star Performer at Commercialization Crossroads
2006
Accounting at Biovail Accounting at Biovail
2004
Grace Bioremediation Technologies Grace Bioremediation Technologies
2005
Diabetogen Diabetogen
2000
DRUG INDUSTRY DRUG INDUSTRY
2018
Note on Contents of a Term Sheet Note on Contents of a Term Sheet
2002
Note on Valuing a Biotech Company Note on Valuing a Biotech Company
2008
Note on Private Company Valuation Note on Private Company Valuation
2001
North Village Capital Private Equity North Village Capital Private Equity
2010
Lululemon Athletica: Pitching an IPO Lululemon Athletica: Pitching an IPO
2011
Valuing Wal-Mart 2010 Valuing Wal-Mart 2010
2011